咪唑并[1,2-a]吡啶-8-羧酸单盐酸盐 | 145335-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 咪唑并[1,2-a]吡啶-8-羧酸单盐酸盐
• 中文别名: 咪唑(1,2-并)吡啶-8-羧酸盐酸盐；咪唑并[1,2-A]吡啶-8-羧酸；咪唑并[1,2-A]吡啶-8-羧酸盐酸盐
• 英文名称: imidazo[1,2-α]pyridine-8-carboxylic acid hydrochloride
• 英文别名: Imidazo[1,2-a]pyridine-8-carboxylic acid hydrochloride；imidazo[1,2-a]pyridine-8-carboxylic acid;hydrochloride
• CAS: 145335-90-6
• 化学式: C₈H₆N₂O₂*ClH
• 分子量: 198.609
• InChiKey: XRQZBGADESKIBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在室温、密封且干燥的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Imidazo[1,2-a]pyridine-8-carboxylic acid HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Imidazo[1,2-a]pyridine-8-carboxylic acid HCl
CAS number: 145335-90-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6N2O2.ClH
Molecular weight: 198.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-a]吡啶-8-羧酸单盐酸盐 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以93%的产率得到imidazo[1,2-α]pyridine-8-carbonyl chloride hydrochloride
  参考文献：
  名称：

  [EN] IMIDAZO[L,2-a]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  [FR] DÉRIVÉS D'IMIDAZO[L,2-?]PYRIDINE UTILISÉS COMME MODULATEURS DU RÉCEPTEUR SÉROTONINERGIQUE 5-HT2A DANS LE TRAITEMENT DES TROUBLES QUI LUI SONT ASSOCIÉS

  摘要：

  公开号：

  WO2009023253A3
• 作为产物：
  描述：

  氯乙醛 、 2-氨基烟酸 在 异丙醇 、 heptanes 作用下， 反应 2.0h， 以to afford the title compound (200.3 g, 92%) as a pale tan solid的产率得到咪唑并[1,2-a]吡啶-8-羧酸单盐酸盐
  参考文献：
  名称：

  IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

  摘要：

  公式（Ia）的咪唑[1,2-α]吡啶衍生物及其制药组合物，可调节5-HT2A 5-羟色胺受体的活性。该化合物及其制药组合物适用于治疗失眠、睡眠障碍、血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、烦躁或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de Ia Tourette综合症、躁狂障碍、器质性或NOS精神病、精神病性障碍、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、糖尿病相关疾病、进行性多灶性白质脑病等治疗方法。本发明还涉及与其他药物分别或联合使用治疗5-HT2A 5-羟色胺受体介导的疾病的方法。

  公开号：

  US20110263592A1

文献信息

• Imidazopyridines as serotonergic 5-HT.sub.3 antagonists
  申请人：G. D. Searle & Co.

  公开号：US05604239A1

  公开（公告）日：1997-02-18

  The imidazopyridines compounds of the present invention are serotonergic 5-HT.sub.3 antagonists. As such they are useful for the treatment of humans and animals wherein antagonism of 5-HT.sub.3 receptors is beneficial. Therapy is indicated for, but not limited to, the treatment of anxiety, psychoses, depression (especially depression accompanied by anxiety), cognitive disorders, substance abuse dependence and withdrawal, gastrointestinal motility disturbancies (including esophageal reflux, dyspepsia, gastric stasis, irritable bowel syndrome), emesis caused by chemotherapeutic agents, and visceral pain. Additionally, the compounds of the present invention may find utility as enhancers of nasal absorption of bioactive compounds.

  本发明的咪唑吡啶化合物是血清素5-HT.sub.3拮抗剂。因此，它们可用于治疗对5-HT.sub.3受体拮抗有益的人类和动物。治疗适用于但不限于焦虑症、精神病、抑郁症（尤其是伴随焦虑的抑郁症）、认知障碍、物质滥用依赖和戒断、胃肠运动障碍（包括食管反流、消化不良、胃排空障碍、肠易激综合症）、化学治疗药物引起的呕吐和内脏疼痛。此外，本发明的化合物可作为生物活性化合物鼻吸收增强剂。
• Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10058549B2

  公开（公告）日：2018-08-28

  rmidazo[1,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  式（Ia）的咪唑并[1,2-α]吡啶衍生物及其药物组合物，可调节 5-HT2A 血清素受体的活性。其化合物和药物组合物用于治疗失眠、失眠症、副失眠和相关睡眠障碍、血小板聚集、冠状动脉疾病、心肌梗塞、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、躁动或其症状、行为障碍、药物性精神病、兴奋性精神病、Gilles de Ia Tourette 综合征、躁狂症、器质性或非器质性精神病、精神障碍、精神病、急性精神分裂症、慢性精神分裂症、非器质性精神分裂症及相关疾病、糖尿病相关疾病、进行性多灶性白质脑病等。本发明还涉及与其他药剂单独或联合给药治疗 5-HT2A 血清素受体介导的疾病的方法。
• Condensed heterocyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0404190B1

  公开（公告）日：1995-10-25
• US5498774A
  申请人：——

  公开号：US5498774A

  公开（公告）日：1996-03-12
• [EN] IMIDAZO[L,2-a]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] DÉRIVÉS D'IMIDAZO[L,2-?]PYRIDINE UTILISÉS COMME MODULATEURS DU RÉCEPTEUR SÉROTONINERGIQUE 5-HT2A DANS LE TRAITEMENT DES TROUBLES QUI LUI SONT ASSOCIÉS
  申请人：ARENA PHARM INC

  公开号：WO2009023253A3

  公开（公告）日：2009-04-09